Table 5 Risk factors of OS.
Risk factor | p value | ||
Age (≥65 vs <65) | 0.01 | ||
Age (≥75 vs <75) | <0.001 | ||
Gender (Male vs Female) | 0.56 | ||
IGHV gene somatic hypermutation status (unmutateda vs mutatedb) | 0.01 | ||
del(13q) (last assessment) (positive vs negative) | 0.46 | ||
del(11q) (last assessment) (positive vs negative) | 0.33 | ||
trisomy 12 (last assessment) (positive vs negative) | 0.59 | ||
del(17p) (last assessment) (positive vs negative) | 0.02 | ||
TP53 mutation status (unmutated vs mutated) | 0.18 | ||
del(17p) positive and/or TP53 mutation (yes vs no) | 0.1 | ||
CIRS score (> 6 vs ≤6) | <0.001 | ||
Other respiratory (YES vs NO) | 0.82 | ||
Asthma (yes vs no) | 0.49 | ||
COPD (yes vs no) | 0.12 | ||
Cardiac Failure (yes vs no) | <0.001 | ||
Arrythmias (yes vs no) | 0.38 | ||
Coronary artery disease (yes vs no) | 0.06 | ||
Other cardiovascular (yes vs no) | 0.16 | ||
Hypertension (yes vs no) | 0.1 | ||
Diabetes (yes vs no) | 0.52 | ||
Chronic renal disease (yes vs no) | 0.02 | ||
Other hematological malignancies (yes vs no) | 0.91 | ||
Other non-hematological malignancies (yes vs no) | 0.87 | ||
Obesity (BMI>30) (yes vs no) | 0.98 | ||
Smoking | 0.8 | ||
Hypogammaglobulinemia (IgG <550 mg/dL) (present vs absent) | 0.08 | ||
CLL treatment status (untreated vs treated) | <0.001 | ||
CLL treatment during COVID-19 (treated vs untreated) | <0.001 | ||
Treated in last 12 months (treated vs untreated) | 0.01 | ||
Multivariate analysis | |||
Risk factor | HR | 95% CI | |
Age (years) | 1.03 | 1.02–1.04 | <0.001 |
Cardiac failure (yes vs no) | 1.79 | 1.04–3.07 | 0.04 |
CLL treatment status (untreated vs treated) | 0.54 | 0.41–0.72 | <0.001 |
